Sistemas de Liberação de Medicamentos; Neoplasias Pancreáticas; Antineoplásicos/farmacologia; Antineoplásicos/uso terapêutico; Compartimento Celular/efeitos dos fármacos; Humanos; Neoplasias Pancreáticas/tratamento farmacológico; Células Estromais/efeitos dos fármacos; Microambiente Tumoral/efeitos dos fármacos

COX-2; CTLs; Cytotoxic T Lymphocytes; DCs; ECM; EGF; FAK; FAP-α; FGF; HSCs; IGF-1; Insulin Growth Factor-1; MDSCs; MMP; PCCs; PDAC; PDGF; PSCs; Pancreatic Stellate Cells; Pancreatic cancer; SERBIPINE2; SHH; SPARC; Stroma; TAMs; TGF-ß; TIMP; Tregs; Tumour microenvironment; VEGF; cyclooxygenase-2; dendritic cells; epidermal growth factor; extracellular matrix; fibroblast activation protein-α; fibroblast growth factor; focal adhesion kinase; hepatic stellate cell; matrix metalloproteinases; myeloid-derived suppressor cells; pancreatic cancer cells; pancreatic ductal adenocarcinoma; platelet-derived growth factor; regulatory T cells (Tregs); secreted protein acidic and rich in cysteine; serine protease inhibitor nexin 2; sonic hedgehog; tPA; tissue inhibitors of metalloproteinases; tissue plasminogen activator; transforming growth factor-ß; tumour associated macrophages; uPA; urokinase-type plasminogen activator; vascular endothelial growth factor; α-SMA; α-smooth muscle actin